Dual-isocenter MR-Linac workflow treats 24-cm prostate and pelvic targets in one patient
A dual-isocenter MR-Linac workflow treated a 24-cm continuous prostate and pelvic target, achieving high gamma passing rates in its first clinical application.
A dual-isocenter MR-Linac workflow treated a 24-cm continuous prostate and pelvic target, achieving high gamma passing rates in its first clinical application.
Vacuum mattress positioning reduced between-session mean-temperature variability from 0.65°C to 0.40°C during superficial hyperthermia in 24 patients.
In 60 patients, adding dosiomic features improved xerostomia prediction only modestly, with a best AUC of 0.60 and no statistically significant advantage.
Across 134 NSCLC patients, proton therapy reduced modeled blood dose by 12% without significantly changing lymphocyte nadir versus photons.
In ten central lung tumors, proton PBS reduced low-dose lung exposure versus VMAT, but some critical-organ doses were less robust.
EXCERPT In 112 proton-treated low-grade glioma patients, 21% developed contrast-enhancing brain lesions, with modeling supporting increased periventricular and LET-dependent injury risk.
Patient-specific fine-tuning increased good cervical target segmentations from 23.7% to 55.8% across 430 CBCT scans in a seven-center evaluation.
In nine-patient planning comparisons, proton CSI achieved the lowest activity-weighted marrow dose at 10.9 Gy versus 16.2–19.2 Gy with photon techniques.
A new framework combines MRI and radiotherapy device risks into six operational classes for prostate SBRT on a 1.5-T MR-linac.
Across 85 nasal vestibule carcinoma patients, HDR brachytherapy evolved toward larger targets and more catheters while reducing dose heterogeneity.
In 414 lung cancer patients, deep-learning dose features modestly improved external prediction estimates, but discrimination gains were not statistically significant.
In 20 high-risk prostate cancer patients, MRI and PSMA-PET boost targets frequently disagreed, with significantly lower dose coverage of PET-defined lesions.
In synchrotron UHDR proton and carbon-ion beams, dose-averaged dose rate better described chamber recombination than conventional field-averaged metrics.
In 16 sinonasal cancer planning cases, LET optimization reduced chiasm LET from 3.1 to 2.3 keV/μm while maintaining target coverage.
Across four proton plans, all 12 recalculations passed 3%/3 mm gamma, but stopping-power choices shifted distal range by up to 1.9 mm.